Selank is a synthetic peptide made of seven amino acids (threonine, lysine, proline, arginine, proline, glycine, proline). It is registered as a medicine in Russia but is not FDA-approved, and no FDA-approved product in the United States contains it.
Selank was developed at the Institute of Molecular Genetics of the Russian Academy of Sciences as an analog of tuftsin, a natural four-amino-acid peptide that comes from a fragment of immunoglobulin G, one of the main antibody proteins in the blood. Researchers added three amino acids (proline, glycine and proline) to the tuftsin sequence to make it more stable in the body.
Selank is often discussed alongside Semax, another peptide developed in Russia. The two are different compounds with different starting sequences.
Proposed mechanisms come mostly from laboratory and animal studies. A 2018 laboratory study from the developing institute reported that Selank changed how GABA, the brain's main calming chemical messenger, binds to its receptors in isolated brain cell membranes. Studies in rats have looked at behavior, memory and a brain growth factor called BDNF. These findings do not show how Selank acts in people.
Most published human research on Selank comes from Russian groups and appears in Russian-language journals. In a 2008 study, 62 patients with generalized anxiety disorder or neurasthenia (a diagnosis of chronic nervous exhaustion used in Russia) received either Selank (30 patients) or the benzodiazepine medazepam (32 patients). The authors reported similar anti-anxiety effects in both groups.
That study was small and compared Selank with another drug rather than with a placebo. Large, independent trials of the kind the FDA requires for approval have not been published.
In Russia, Selank is registered as 0.15% nasal drops. The Russian drug reference RLS lists anxiety states, neurasthenia and stress-related disorders among its indications, and lists pregnancy, breastfeeding and age under 18 among its contraindications.
Registration in one country does not transfer to another. In the United States, a drug must be approved by the FDA before it can be legally marketed as a medicine.
Current status: Not FDA-approved. No product containing Selank is an approved medicine in the United States.
Compounding: Selank acetate was once in Category 2 of the FDA's interim 503A lists, the group of bulk substances that raise significant safety risks. It was removed in September 2024 after the nominators withdrew their nominations. As of the FDA's May 14, 2026 update, Selank is not in Category 1 and is not on the 503A bulks list, so it does not meet the conditions for 503A compounding.
Selank is also not a dietary supplement. A peptide that has not been approved as a drug does not become legal to market simply by being labeled "for research purposes only."
The FDA's safety summary says compounded selank acetate may pose a risk of immunogenicity (an unwanted immune response) for certain routes of administration because of possible aggregation and peptide-related impurities, and that the FDA lacks important information about safety issues when Selank is given to humans.
The Russian product information lists allergic reactions and an unpleasant taste among possible side effects. U.S. regulators have not reviewed that labeling.
Selank is not named on the World Anti-Doping Agency (WADA) 2026 Prohibited List. Athletes should confirm the status of any substance with their anti-doping organization.
Peptide Labs does not sell this compound. This page is general information, not medical advice. We are not a pharmacy, we do not supply Selank, and we do not point readers to anyone who does.
For personal medical questions, including questions about anxiety, the right person to ask is a licensed healthcare provider. Several FDA-approved options exist, and a clinician can discuss which, if any, suit you.
See the full list of compound profiles in the Peptide Guide. For the related Russian-developed peptide, see our profile of Semax, or read whether peptides are legal in the U.S.